NCT00810485View on ClinicalTrials.gov

ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)

PHASE2CompletedINTERVENTIONAL

Enrollment

298

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2009

Conditions

Gastroesophageal Reflux

Interventions

DRUG

ADX10059

oral administration

DRUG

ADX10059

oral administration

DRUG

ADX10059

oral administration

DRUG

ADX10059 Matching Placebo

oral administration

Trial Locations (40)

Unknown

Little Rock

Tucson

Anaheim

San Diego

Colorado Springs

Jacksonville

Port Orange

Moline

54, Kansas City

62, Kansas City

Jackson

Setauket

Harrisburg

High Point

Huntersville

Raleigh

Winston-Salem

Fargo

Cleveland

Oklahoma City

Philadelphia

Charleston

Germantown

71, Nashville

73, Nashville

Baytown

Houston

Waukesha

Bordeaux

Colombes

Lyon

Nantes

Nice

Rouen

Dresden

Garmisch-Partenkirchen

Magdeburg

Munich

Amsterdam

Sankt Gallen

Sponsors

Lead Sponsor

Addex Pharma S.A.

All Listed Sponsors

lead

Addex Pharma S.A.

INDUSTRY

NCT00810485 - ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD) | Biotech Hunter | Biotech Hunter